相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty
Ralph M. Meyer
JOURNAL OF CLINICAL ONCOLOGY (2017)
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET ONCOLOGY (2017)
The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study
J. M. Zaucha et al.
ANNALS OF ONCOLOGY (2017)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Radiation Therapy for Hodgkin Lymphoma-Can It Be Administered More Safely if Necessary?
David J. Straus et al.
JAMA ONCOLOGY (2016)
Late Morbidity and Mortality in Patients With Hodgkin's Lymphoma Treated During Adulthood
Matthew J. Matasar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Late Morbidity and Mortality in Patients With Hodgkin's Lymphoma Treated During Adulthood
Matthew J. Matasar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
N. Mounier et al.
ANNALS OF ONCOLOGY (2014)
Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients
Theodore Girinsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
John M. M. Raemaekers et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
ON SAMPLE SIZE CALCULATION FOR COMPARING SURVIVAL CURVES UNDER GENERAL HYPOTHESIS TESTING
Sin-Ho Jung et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2012)
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
David J. Straus et al.
BLOOD (2011)
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Report on the First International Workshop on interim-PET scan in lymphoma
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2009)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Eldad J. Dann et al.
BLOOD (2007)
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
Theodore Girinsky et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
DJ Straus et al.
BLOOD (2004)
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
V Diehl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
